Corvus Pharmaceuticals (CRVS) said late Thursday that new interim data from a phase 1 clinical trial of soquelitinib to treat moderate to severe atopic dermatitis showed a "favorable" safety and efficacy profile.
The company found "earlier and deeper responses" in group 3, which received 200 milligrams twice a day, compared with groups 1 and 2, which received 100 mg twice daily and 200 mg once daily.
Corvus said that all three groups showed "significant responses" in the soquelitinib treatment groups, compared with placebo for clinically significant endpoints.
Atopic dermatitis is a skin condition characterized by dry, itchy, and inflamed skin.
Shares of the company were up 37% in recent premarket activity Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。